EPITA Specialty Update Symposium

New challenges in pancreas and islets transplantation

SUNDAY 24 SEPTEMBER 2017 | 09:00-12.50

09.00 – 10.40 SESSION 1. New challenges for a fair allocation (recipient)

CHAIRS: Steve White, United Kingdom
               Helmut Arbogast, Munich, Germany

  • Challenges in different countries. Eurotransplant is in there with the other countries
    Eelco de Koning, Leiden, The Netherlands
  • Experiences with a common waiting list for islets transplant in the United Kingdom
    James Show, United Kingdom
  • New allocation system: the Swiss solution
    Roger Lehmann, Zurich, Switzerland
  • What about France?
  • Pancreas allocation in North Italy Transplant program (NITp)
    Massimo Cardillo, Milan, Italy
  • A history talk : The first two kidney/pancreas transplants - University of Minnesota, 50 years ago
    Frederick Merkel, Chicago, United States

​​​​​​​10.40 – 11.10 Break

11.10 – 12.50 SESSION 2. New challenges in donation (donor)

CHAIRS: Lorenzo Piemonti, Milan, Italy
               Johann Pratschke, Berlin, Germany

  • What is the crucial information for accepting an organ? Are scoring systems helpful?
    Raja Kandaswamy, Minneapolis, United States
  • Update on marginal donor utilization
    Peter Friend, Oxford, United Kingdom
  • Decreasing numbers for beta-cell replacement: what is the reason?
    Antonio Secchi, Milan, Italy




OBJECTIVES | To review recent developments in pancreas and islet transplantation.

TARGET AUDIENCE |Transplant surgeons and physicians, transplant coordinator, nurses and medical student with an interest in transplantation of pancreas and islets.


The European Pancreas and Islet Transplantation Association is a section of ESOT founded to provide a Forum  for the pancreas and islet transplantation community in Europe.

GOALS |To facilitate the exchange of information of the field of pancreas and islet transplantation.

AIM |The aim of EPITA is to contribute to the development of the pancreas and islet transplantation field and of alternate forms of beta-cell replacement therapy for the benefit of patients suffering from type 1 diabetes.